Please assess the completion status of the following clinical trial:

Trial Title: Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of coronary endothelial dysfunction based on coronary angiogram and acetylcholine comprehensive coronary physiology study~* Able to provide informed written consent and willing to participate in all required study follow-up assessments~Exclusion Criteria:~* Acute coronary syndrome or continuous/ongoing chest pain - unremitting and unresponsive to nitroglycerin or rest - persisting 4 or more days before stent placement. If the chest pain syndrome is transient and/or intermittent - even if it began more than 3 days prior to admission - the patient is not excluded.~* Subjects in cardiogenic shock (systolic pressure \< 80mm/Hg, on vasopressors or intraaortic counter pulsation) at the time of consenting. Subjects who recover from cardiogenic shock by the time of consenting are eligible.~* Subjects unable to receive antiplatelet agents (e.g. aspirin, clopidogrel, ticlopidine,prasugrel, etc).~* Abnormal laboratory values (Hgb \<11 mg/dL; glomerular filtration rate (GFR)\<50; liver function tests (LFTs)\>2x upper limit of normal).~* Subjects receiving warfarin who have an international normalized ratio (INR) \>2 at the end of the screening phase or with major bleeding requiring active transfusion support.~* Subjects with severe cardiac valvular disease expected to undergo surgery within 1 year.~* Subjects with known severe immunodeficiency states (AIDS).~* Significant coronary artery disease on coronary angiogram~* Cirrhosis requiring active medical management.~* Malignancy requiring active treatment (except basal cell skin cancer).~* Subjects with documented active alcohol and /or other substance abuse.~* Females of child bearing potential unless a pregnancy test is negative within 7 days of the bone marrow harvest.~* Re-occlusion of the infarct related artery (IRA) prior to the infusion procedure.~* Planned revascularization intervention during the next 6 months. (A second PCI can be performed if done prior to qualifying cardiovascular magnetic resonance imaging (CMR) at least 96 hours post primary PCI).~* Participation in an ongoing investigational trial.~* Active or suspected bacterial infection requiring systemic intravenous antibiotics.~* Additional factors deemed unsuitable for trial enrollment per discretion of principal investigator~* Inmates

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Subjects with Endothelial Dysfunction (Type: EXPERIMENTAL): Subjects will be treated with Granulocyte Colony-Stimulating Factor (G-CSF) for 5 days at a dose of 5 mg/kg twice daily. When count of CD34+ cells is sufficient, the CD34+ cells will be collected by apheresis. Autologous CD34+ cells will be injected into the subjects at a rate of 10 ml/min.

Based on this trial design, predict the completion outcome and termination type (if applicable).